Pharming Group (NASDAQ:PHAR – Get Free Report) shares were down 2.6% during trading on Tuesday . The stock traded as low as $7.60 and last traded at $7.60. Approximately 1,676 shares changed hands during trading, a decline of 63% from the average daily volume of 4,540 shares. The stock had previously closed at $7.80.
Wall Street Analyst Weigh In
Separately, HC Wainwright reissued a “buy” rating and set a $37.00 price objective on shares of Pharming Group in a report on Thursday, August 1st.
Get Our Latest Stock Report on PHAR
Pharming Group Trading Up 1.3 %
Pharming Group (NASDAQ:PHAR – Get Free Report) last announced its quarterly earnings results on Thursday, August 1st. The company reported ($0.01) EPS for the quarter. Pharming Group had a negative net margin of 4.65% and a negative return on equity of 5.69%. The business had revenue of $74.09 million during the quarter, compared to the consensus estimate of $71.95 million. During the same period in the previous year, the business posted $0.02 EPS. As a group, equities research analysts predict that Pharming Group will post -0.15 earnings per share for the current fiscal year.
Institutional Trading of Pharming Group
An institutional investor recently raised its position in Pharming Group stock. Silverberg Bernstein Capital Management LLC lifted its stake in shares of Pharming Group (NASDAQ:PHAR – Free Report) by 32.3% during the second quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 23,435 shares of the company’s stock after acquiring an additional 5,725 shares during the quarter. Silverberg Bernstein Capital Management LLC’s holdings in Pharming Group were worth $196,000 at the end of the most recent reporting period. 0.03% of the stock is owned by hedge funds and other institutional investors.
About Pharming Group
Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company offers RUCONEST, a recombinant C1 esterase inhibitor for the treatment of acute attacks in adult and adolescent patients with acute hereditary angioedema (HAE); and Joenja (leniolisib), an oral small molecule PI3K? inhibitor for the treatment of activated phosphoinositide 3-kinase delta syndrome.
Featured Stories
- Five stocks we like better than Pharming Group
- Investing In Preferred Stock vs. Common Stock
- Edgewise Therapeutics Soars 50%: Key Reasons Behind the Surge
- Are Penny Stocks a Good Fit for Your Portfolio?
- How the Fed’s Rate Cut Could Supercharge These 3 ETFs
- 3 Home Improvement Stocks that Can Upgrade Your Portfolio
- Microsoft Stock: 3 Reasons It’s Ready to Crush Q4
Receive News & Ratings for Pharming Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pharming Group and related companies with MarketBeat.com's FREE daily email newsletter.